| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $2.0M | -67.3% |
| R&D Expense | $145.6M | +75.2% |
| SG&A Expense | $34.3M | +37.4% |
| Operating Income | -$177.9M | -74.7% |
| Income Tax | $0 | — |
| Net Income | -$162.3M | -91.1% |
| EPS (Basic) | -$4.20 | -64.7% |
| EPS (Diluted) | -$4.20 | -64.7% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $51.1M | +124.1% |
| Short-term Investments | $353.2M | +39.9% |
| Accounts Receivable | $52K | -93.6% |
| Current Assets | $409.4M | +45.8% |
| Total Assets | $530.9M | +42.0% |
| Current Liabilities | $30.7M | +66.6% |
| Total Liabilities | $37.5M | +74.3% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$129.1M | -65.1% |
| Capital Expenditures | $213K | +102.9% |
| Investing Cash Flow | -$122.8M | +57.2% |
| Financing Cash Flow | $280.1M | +9.6% |
| Free Cash Flow | -$129.3M | -65.1% |
| Stockholders' Equity |
| $493.4M |
| +40.0% |